Home

The firm

Team

Portfolio

Investors

Connect

Cookie Policy

Cookie Policy

Here you can read about Nordicus Partners Corporation’s policy for the use of cookies by visiting nordicuspartners.com. When visiting Nordicus Partners Corporation’s website you agree to the following policy on cookies.

Private policy

WHAT IS A COOKIE?

A cookie is a small text file that is stored in the web browser on your computer, smartphone, iPad, or whatever else you go online with. Cookies enable us to identify your computer etc. and gather information about your online behavior, including which pages and features, are visited with your browser, and ensure that it works technically. In some cases, the cookies are needed to get a website to function properly. A cookie is static and cannot spread computer viruses or other means to distribute malicious programs. It is anonymous and contains no personal data. Cookies are used by virtually all websites.

TYPES OF COOKIES

There are two types of cookies: session cookies and persistent cookies. Session cookies are automatically deleted from the browser when you close it. Persistent cookies are stored on your device for a specified time period after which they expire.

A distinction is also made between first-party cookies and third-party cookies. First-party cookies are set by the website you visit third-party cookies are set by a third party that has elements embedded into the web page you visit. Third-party cookies set include web analytics, for example, Google Analytics and WebTrends.

This Cookie Policy applies only to nordicuspartners.com. Clicking functions navigating to other websites have NORDICUS Partners Corporation’s no responsibility or control over the cookies used.

 

HOW TO AVOID OR DELETE COOKIES

If you do not want cookies from nordicuspartners.com you can always block all cookies, delete existing cookies on your computer or receive a warning before a cookie is stored. All browsers allow you to erase cookies individually or all at once. How you do this depends on which browser you use. Follow the links below will get directions to your browser. Remember that if you use multiple browsers, and delete cookies in all of them.

How to delete cookies in Microsoft Internet Explorer
How to delete cookies in Safari browser
How to delete cookies in Google Chrome browser
How to delete cookies in Mozilla Firefox browser
How to delete cookies from Android phones
How to delete cookies in Opera browser
How to delete cookies on iPad, iPhone, iPod touch
How to delete cookies from Windows Phone
How to delete cookies from Windows Phone 7

 

WHAT HAPPENS IF YOU DO NOT ACCEPT OR DELETE COOKIES

If you choose to block all cookies or delete existing cookies on your computer, you can still read text on nordicuspartners.com. However, there may be features and services you cannot use because they require that the site can remember the choices you make.

 

RULES

The Rules that apply to Nordicus Partners Corporation’s use of cookies can be found below:

Order on Cookies
Guide cookies

 

CONTACT

Please feel free to contact us if you have further questions about the use of cookies on nordicuspartners.com.

Kim Mücke

Member, Board of Directors

Kim T. Mücke is a Danish state authorized public accountant (authorization deposited in 2025). He was partner with Deloitte (Denmark) in the period 2002 to 2022 where he – among others – served as signing partner for various listed companies including companies that underwent IPO processes. In the years 2023-2024, Mr. Mücke was Head of Corporate Clients for BDO (Denmark). From 1 January 2025, Mr. Mücke has started as independent advisor,specialized in financial reporting, risk management and corporate governance. Mr. Mücke has a master’s degree in Auditing and Accounting from the Copenhagen Business School.

Andrew Ritter

Member, Board of Directors

Mr. Ritter is a seasoned healthcare executive with over two decades of leadership experience across biotechnology, digital health, and other healthcare technologies. He has successfully led multiple company exits, taken a company public on NASDAQ, and advised leading private equity and venture capital firms throughout the investment lifecycle.

He began his career as the founder and CEO of Ritter Pharmaceuticals, a microbiome-based biotech company. Over 17 years, he advanced the company from early-stage development through Phase III clinical trials, led its IPO onto the NASDAQ, and later merged the company with QualigenTherapeutics. Following that success, Mr. Ritter led a turnaround and successful exit of Docbot, an AI-driven MedTech company. He is currently an Entrepreneur in Residence at Khosla Ventures, and serves as CEO of portfolio company Cairns Health, an AI-powered remote care solutions to support Home and Senior Care.

He has also served as a founding board member of Myosin Therapeutics, a biotech spin-out from Scripps Research, where he helped secure the company’s initial financing and supported its early growth. Mr. Ritter holds a B.A. in Political Science from the University of Southern California and an M.B.A. from the Wharton School of the University of Pennsylvania.